May 3, 2022 (Chicago, IL) - Today, Synapticure, a teleneurology company providing personalized care for people living with ALS (Amyotrophic Lateral Sclerosis) and their families, announced two key hires as part of its expanded leadership team. Dr. Eric Anderson is Synapticure’s new Vice President, Clinical Operations and Care Delivery and Robert Potts is Head of Telemedicine Operations. Together with Synapticure’s founding team members, investors and advisors, Anderson and Potts will work to scale Synapticure’s care platform across the country including the hiring of additional neurologists.
“We are building Synapticure to be a full stack teleneurology platform that provides best in class care in neurodegeneration, starting with people living with ALS,” said Sandra Abrevaya, Co-Founder and CEO of Synapticure. “Eric and Robert are bringing expertise in neurology and telemedicine alongside innovative leadership that will accelerate the rate at which we can create a new paradigm for care in neurodegeneration that gives patients the services they need and deserve today."
An innovative physician-scientist, Dr. Eric Anderson has been recognized as a national leader in telemedicine and mobile health, holding several leadership positions throughout his career with the American Academy of Neurology including the past Chairperson of the Telemedicine Workgroup. He most recently served as Director of Scientific Affairs, Director of the National EEG Network, and Past Chair of Neurology for SOC Telemed, a leader in emergency telemedicine services, as well as Medical Director of CortiCare, a leading provider of technology and electroencephalographic (EEG) services to the hospital and physician office markets. As Vice President of Clinical Operations and Care Delivery, Anderson will expand the care team as well as oversee all care providers and design, build, and innovate Synapticure’s practice structure. In partnership with Synapticure’s Senior Medical Advisor and ALS expert Jinsy Andrews, he will develop and implement the practice’s clinical protocols and services and direct a high-empathy provider culture that delivers a high-quality patient experience.
An experienced healthcare IT executive, Robert Potts joins Synapticure from Amwell, a leading global telehealth platform, where he was most recently Director of Operations. As Head of Telemedicine Operations, Potts will lead the design of and development of solutions to help streamline the provider and patient experience through Synapticure’s telemedicine platform as the company uses data, technology and innovation to disrupt the way neurodegenerative disease is treated.
Synapticure is dedicated to creating the future of neurodegenerative disease patient care. Today, Synapticure is focused on providing better treatment and care for all people living with ALS through a full-stack teleneurology platform, built by and for those living with ALS. Co-founded by Brian Wallach, Sandra Abrevaya, Peter Wallach, Jason Langheier and Jonathan Hirsch, Synapticure is headquartered in Chicago, Illinois. To learn more, please visit synapticure.com or follow us on Twitter, LinkedIn, Facebook, and Instagram for updates.
ALS is 100% fatal and affects more than 30,000 people in the U.S. The lifetime risk of developing ALS is 1 in 300, the same as Multiple Sclerosis. Each year, more than five thousand people are diagnosed with ALS in the US alone. This number is expected to nearly double by 2060. People living with ALS, on average, live two to five years after diagnosis, and nearly half live more than 50 miles away from the closest ALS multidisciplinary clinic.
About Parkinson’s Disease
Parkinson's disease is a progressive neurodegenerative disease that causes nerve cells (or neurons) in the area of the brain that controls movement to weaken and/or die. More than 10 million people worldwide are currently living with Parkinson's disease. The number of people diagnosed with with Parkinson’s Disease is expected to rise from 900,000 to 1.2 million by 2030. What causes Parkinson's remains largely unknown. Genetics cause about 10 to 15 percent of all Parkinson's. The other 85 to 90 percent of cases are classified as sporadic (or occasional). Although there is no cure, treatment options vary and include medications and surgery.